#ESMO26 Dr. @dplanchard presents data on ctDNA clearance in EGFR+ NSCLC from FLAURA2. Baseline ctDNA in 69% of osi/chemo and 77% in osi mono with similar clearance rates in both ar

Stephen V Liu, MD· @StephenVLiu · X·2026-10-24 14:44· 1 day agoScore70

Body · original

#ESMO26 Dr. @dplanchard presents data on ctDNA clearance in EGFR+ NSCLC from FLAURA2. Baseline ctDNA in 69% of osi/chemo and 77% in osi mono with similar clearance rates in both arms. ctDNA clearance prognostic but benefit of chemotherapy seen regardless. #ESMOAmbassadors

109 views · 3 likes · 1 repost · 0 replies

Conference abstracts

2700ROmatched by Rapid oral 1: NSCLC, metastatic

Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort

https://esmocongress.esmo.org

806PNCT04787341 NCT04787341 NCT04787341matched by Colon cancer

Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer

https://esmocongress.esmo.org

NCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

Source: Stephen V Liu, MD · x.com